Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.39 |
| ▸ | PREP | P48147 | 9/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31486384 | 0.93 | MAPK14 (0.35) | RPS6KB1PREPMAPK14 | |
| SCHEMBL31486305 | 0.87 | MAPK14 (0.37) | PREPMAPK14JAK3 | |
| SCHEMBL31486537 | 0.84 | RPS6KB1 (0.39) | RPS6KB1PREPMAPK14AURKAJAK2 | |
| SCHEMBL31486500 | 0.83 | WDR5 (0.34) | PREPJAK2JAK3 | |
| Trifluoroacetic Acid SCHEMBL31486443 | 0.82 | F2 (0.41) | RPS6KB1 | |
| SCHEMBL31486475 | 0.81 | PREP (0.43) | PREPMAPK14 | |
| SCHEMBL31486600 | 0.81 | F2 (0.43) | — | |
| SCHEMBL31486419 | 0.81 | F7 (0.41) | RPS6KB1PREP | |
| SCHEMBL30929451 | 0.80 | F2 (0.44) | RPS6KB1PREPTLR2RIPK1 | |
| SCHEMBL31486531 | 0.80 | RPS6KB1 (0.36) | RPS6KB1PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025076476-A2 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, SPINT2, SERPINB1 | RPS6KB1 2675/4885PREP 140/4885MAPK14 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.